Format

Send to

Choose Destination
J Antimicrob Chemother. 1998 Oct;42(4):535-8.

Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction.

Author information

1
Servei de Microbiologia, Hospital de Sant Pau, Barcelona, Spain.

Abstract

Between 1994 and 1996 we detected 28 out of 7054 (0.4%) clinical isolates of Escherichia coli with abnormal or reduced inhibition diameters to co-amoxiclav and ceftazidime in a disc diffusion test. The increased MIC of ceftazidime (1-32 mg/L) and the effect of synergy between this antibiotic and co-amoxiclav according to the disc diffusion test suggest the presence of an extended-spectrum beta-lactamase. However, enzymatic characterization and the nucleotide sequence confirm the hyperproduction of the SHV-1 enzyme.

PMID:
9818756
DOI:
10.1093/jac/42.4.535
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center